| Montgomery Children's Specialty Center | |
| 2853 Forbes Drive, Montgomery, Alabama 36110 | |
| (334) 261-3445 | |
| Name | Montgomery Children's Specialty Center |
|---|---|
| Location | 2853 Forbes Drive, Montgomery, Alabama |
| Certified By | Medicaid |
| No. of Certified Beds | 54 |
| Occupancy Rate | 80.74% |
| Medicare ID (CCN) | 01A208 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1225347495 |
| Organization Name | MONTGOMERY CHILDREN'S SPECIALTY CENTER, LLC |
| Doing Business As | MONTGOMERY CHILDREN'S SPECIALTY CENTER |
| Address | 2853 Forbes, Montgomery, AL 36110 |
| Phone Number | 334-262-6421 |
News Archive
Nearly 10 years after the greatest human-made disaster in U.S. history- the destruction of the World Trade Center (WTC) towers - there has been little research documenting the attacks' consequences among those most directly affected - the survivors who escaped the World Trade Center towers.
Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
› Verified 3 days ago
| NPI Number | 1336137488 |
| Organization Name | FATHER WALTER MEMORIAL CHILD CARE CENTER |
| Address | 2815 Forbes Dr, Montgomery, AL 36110 |
| Phone Number | 334-262-6421 |
News Archive
Nearly 10 years after the greatest human-made disaster in U.S. history- the destruction of the World Trade Center (WTC) towers - there has been little research documenting the attacks' consequences among those most directly affected - the survivors who escaped the World Trade Center towers.
Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Nearly 10 years after the greatest human-made disaster in U.S. history- the destruction of the World Trade Center (WTC) towers - there has been little research documenting the attacks' consequences among those most directly affected - the survivors who escaped the World Trade Center towers.
Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 8.16 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.1 | 5.51 |